You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Chia Tai Tianqing Pharmaceutical Group has agreed to copromote Genetron's HCCscreen test in hospitals where the pharma firm has an established presence.
The company's HCCscreen assay will be used in a liver cancer screening public health initiative, generating real-world data on the test's clinical validity and impact.
The Chinese company is branching out from its core genomics business to liquid biopsy cancer screening and monitoring as it eyes areas for global expansion.
The Chinese company reported revenues of RMB112.0 million ($16.5 million), driven by growth in sales of both its LDT services and IVD products.
The firm is engaged in multiple clinical validation trials and aims to raise more than $100 million to launch its Helio Liver Test in the US early next year.
In PNAS this week: rearrangements found in acute myeloid leukemia, DNA double-strand break repair patterns in model of hepatocellular carcinoma, and more.
The firm presented initial study results from the test, which identifies six cancers, showing overall sensitivity at 86 percent and specificity of 95 percent.
The company's approach combines whole-genome sequencing, CRISPR, liquid biopsy, and gene therapy to target cancer cells with gene fusions.
A new study aims to compare the detection performance of Helio Health's circulating tumor DNA assay with that of other screening modalities.
The "EV Click Chip" process involves collecting and purifying extracellular vesicles from a blood sample before performing RT-ddPCR to identify up to 10 early-stage HCC biomarkers.
According to the Associated Press, genetic genealogy has helped law enforcement officials identify an unknown victim of the Green River Killer.
Imperial College London researchers are shifting away from testing a COVID-19 vaccine to focus on combating newly emerging SARS-CoV-2 variants, the Independent says.
In PNAS this week: target to reduce chemotherapy-induced cardiac injury, tool finds ancient endogenous RNA viruses, and more.
Moderna reports its vaccine is effective against new SARS-CoV-2 strains, though it is also developing a booster, according to the New York Times.